Please assess the completion status of the following clinical trial:

Trial Title: BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have vomited at least twice in the 4 hours preceding signing informed consent. A vomiting episode is defined as an episode of forceful expulsion of stomach contents. Retching if a patient has already emptied his or her gastric contents is also considered vomiting episode. A distinct episode is characterized by a clear break in vomiting activity of at least 5 minutes~* Emesis must have been nonbloody (streaks of blood presumed due to force of retching are allowed)~* All patients (and a parent or guardian for patients \<age 18) must sign informed consent.~Exclusion Criteria:~* Severe dehydration. Severe dehydration is defined as two or more of the following criteria in the presence of decreased intake and increased output due to vomiting or diarrhea: Absent or severely decreased urine output; weak pulse and/or low blood pressure; parched mucous membranes; lethargy, confusion, delirium or loss of consciousness~* Signs and symptoms severe enough to require immediate parenteral hydration and/or parenteral antiemetic medication~* Temperature\>39.0~* Likely etiologies for acute vomiting and diarrhea other than acute infectious or toxic gastroenteritis or gastritis. This includes signs of an acute abdomen, which may require surgical intervention~* Chemically-induced gastroenteritis, e.g., from alcohol, other drugs of abuse or other irritant chemicals~* Use within 24 hours of study entry of specific medication for treatment of nausea and/or vomiting, e.g., 5-HT3 antagonists or phenothiazines, or receipt of any IV fluid for any reason. Nonspecific gastrointestinal remedies, such as antacids, proton pump inhibitors and homeopathic remedies, are permitted.~* Congestive heart failure, bradyarrhythmia (baseline pulse\<55/min), known long QT syndrome~* Patient who have known QTc prolongation \> 450 msec, noted on prior or screening ECG, or who are taking medication known to cause QT prolongation. Note: for current list of medications known to cause QT prolongation see: https://www.crediblemeds.org/healthcare-providers/drug-list/ Use list showing drugs with known risk TdP.~* Known underlying disease which could affect assessment of hydration or modify outcome of treatment, e.g., renal failure, diabetes mellitus, liver disease, alcoholism. Patients with type 2 diet-controlled diabetes mellitus whose baseline blood glucose is \<200 may be entered into the study~* Abdominal surgery within the past 3 months~* History of bariatric surgery or bowel obstruction at any time~* Hypersensitivity or other known intolerance to ondansetron or other 5-HT3 antagonists~* Patient has taken apomorphine within 24 hours of screening~* Patient has previously participated in this study~* Patient has participated in another interventional clinical trial, for any indication, in the past 30 days~* For women of childbearing potential: documented or possible pregnancy.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- RHB-102 (Type: EXPERIMENTAL): RHB-102, Bimodal Release Ondansetron Tablets
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).